Altimmune to Present Pemvidutide Data at AASLD 2026
Altimmune will present 48-week IMPACT Phase 2b analyses and preclinical data on pemvidutide, including fibrosis-marker reductions, GI tolerability and reduced alcohol intake in a hamster model.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
3 results loaded, newest first. End of these results.
Altimmune to Present Pemvidutide Data at AASLD 2026
The company says an oral presentation will include new preclinical data showing reduced alcohol intake with pemvidutide. It also cited Phase 2b IMPACT findings of improved liver fibrosis and inflammation, with generally favorable gastrointestinal tolerability.
Altimmune to present pemvidutide data at AASLD 2026
Altimmune says it will present new pemvidutide data on serious liver diseases at AASLD The Liver Meeting 2026.